文献速递角膜与眼表疾病

2014-2021年美国IRIS®登记系统中眼表鳞状上皮肿瘤的发病率与人口学特征

US Incidence and Demographics of Ocular Surface Squamous Neoplasia in the IRIS® Registry 2014-2021.
PubMed 文献 · Ophthalmology · 2025-04-19

该回顾性分析利用IRIS®登记系统2014-2021年数据,纳入13924只眼(13383例患者),确定美国眼表鳞状上皮肿瘤(OSSN)的年发病率为每10万患者年3.4例,发病率从2014年至2021年增加2.9倍,患者以老年、白人、男性为主。

要点

  • IRIS®登记系统中OSSN年发病率为每10万患者年3.4例,2014年至2021年发病率增加2.9倍。
  • 患者平均年龄67岁,88%超过50岁,62%超过65%;63.8%为男性,65%为白人,10%为西班牙裔。
  • 44%的OSSN眼接受了手术切除;在接受初始局部药物治疗的患者中,62%使用干扰素α-2b。

核心结论

  • 本研究利用IRIS®登记系统作为OSSN发病率和人口学特征的数据库,人口学结果与其他研究一致,显示老年、白人和男性患者发病率更高。
  • 截至2021年,美国每年至少有2100例新发OSSN病例,且发病率从2014年至2021年有所增加。
  • 2014年至2021年,局部免疫化学治疗药物干扰素(IFN)仍是OSSN常用的治疗方式。

研究设计与样本

  • 回顾性分析IRIS®登记系统中所有具有OSSN国际疾病分类(ICD)第9版和第10版编码的患者。
  • 共纳入13383例患者的13924只独特眼。

主要发现

  • 2014年至2021年IRIS®登记系统中OSSN年发病率为每10万患者年3.4例,登记系统内OSSN发病率从2014年至2021年增加2.9倍。
  • 患者平均年龄67岁,88%的患者超过50岁,62%超过65岁。
  • 受影响队列的人口学特征为63.8%男性、65%白人、10%西班牙裔。
  • 40%的OSSN患者有吸烟史,39%的患者位于美国南部各州(基于美国人口普查分类)。
  • 44%的OSSN眼接受了手术切除;在接受初始局部药物治疗的患者中,62%使用干扰素α-2b治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the incidence and demographics of ocular surface squamous neoplasia (OSSN) in the United States using the IRIS® Registry (Intelligence Research in Sight). DESIGN: Retrospective analysis of all patients with OSSN International Classification of Diseases (ICD) 9th and 10th Revision codes. PARTICIPANTS: A total of 13 924 unique eyes from 13 383 patients. METHODS: The ICD 9th and 10th revision codes were used to identify eyes with OSSN. MAIN OUTCOME MEASURES: Incidence of OSSN, demographic information, diagnosis, risk factors, and frequency of use for current treatments. RESULTS: The annual incidence from 2014 to 2021 in the IRIS Registry was 3.4 per 100 00 patient-years. The incidence within the registry of OSSN increased 2.9 times from 2014 to 2021. The average age was 67 years, with 88% of patients older than 50 years and 62% older than 65 years. Demographics of the affected cohort were 63.8% male, 65% White, and 10% Hispanic. Forty percent of patients with OSSN had a history of smoking, and 39% of patients were in southern US states based on US Census classification. Surgical excision was performed on 44% of OSSN eyes. Of the patients with primary topical therapy, 62% were treated with interferon (IFN) alfa-2b. CONCLUSIONS: This study used the IRIS Registry as a database for the incidence and demographics of OSSN. Our demographic results are consistent with other studies showing a higher incidence in older, White, and male patients. This study demonstrated that as of 2021 there are at least 2100 new OSSN cases per year in the United States and that incidence increased from 2014 to 2021. The use of the topical immuno-chemotherapy IFN remained a popular treatment modality for OSSN from 2014 to 2021. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Meide EVH, Ferguson TJ, Karp CL, et al. US Incidence and Demographics of Ocular Surface Squamous Neoplasia in the IRIS® Registry 2014-2021. Ophthalmology. 2025. PMID: 40258494. doi:10.1016/j.ophtha.2025.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。